Index,NCTId,Condition,Change,Reference,Variable,Timepoint,Endpoint Art
0,NCT01814787,Type 2 Diabetes,Number Of Children With Documented Risk Factors For Type 2 Diabetes,Not Mentioned,Not Mentioned,12 Months,Primary Endpoint
1,NCT01814787,Type 2 Diabetes,Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
2,NCT01346033,Type 2 Diabetes,Validation Of Scout Ds Algorithm For Detecting Known Type 2 Diabetes,Not Mentioned,Not Mentioned,1 Day,Primary Endpoint
3,NCT01346033,Type 2 Diabetes,Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
4,NCT04765631,Type 2 Diabetes,"The Main Outcome Is The Comparison Of Total Volumetric Bone Mineral Density (Vbmd) At The Tibia And Distal Radius, In Type 2 Diabetics Compared To Non-Diabetic Subjects.",Not Mentioned,Not Mentioned,At Inclusion For Qualyor Patients. (The Hrpqct Measure Considered In This Study Is Realised At The First Visit Just After Inclusion Of The Patient For The Qualyor Patients),Primary Endpoint
5,NCT04765631,Type 2 Diabetes,Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
6,NCT03979768,Type2 Diabetes,Number Of Participants With Undiagnosed Type 2 Diabetes,Not Mentioned,Not Mentioned,2 Months,Primary Endpoint
7,NCT03979768,Type2 Diabetes,Explore If There Was Any Difference In The Number Of Participants With A High Risk Of Developing Type 2 Diabetes In The Risk Test Only (Rto)- Group And The Group That Also Offered A Hba1C-Measurement (Hba1C-Group),Not Mentioned,Not Mentioned,Baseline,Secondary Endpoint
8,NCT02286128,Type 2 Diabetes,Correlation Between Nf-Кb Dependent-Proinflammation Markers And Osteoblast-Specific Gene Expression In The Msc To Measure The Effects Of Nf-Кb Dependent-Proinflammation On Differentiation Potential Toward Osteoblast In Type 2 Diabetes.,Not Mentioned,Not Mentioned,2-4 Weeks,Primary Endpoint
9,NCT02286128,Type 2 Diabetes,Correlation Between Nf-Кb Dependent-Proinflammation Markers And Apoptotic Marker Expression In The Msc To Measure Effects Of Nf-Кb Dependent-Proinflammation On Cellular Apoptosis In Type 2 Diabetes.,Not Mentioned,Not Mentioned,2-4 Weeks,Secondary Endpoint
10,NCT02286128,Type 2 Diabetes,Correlation Between Nf-Кb Dependent-Proinflammation Markers And The Expression Of Rage And Its Downstream Signals In The Msc To Measure Effects Of Nf-Кb Dependent-Proinflammation On Cellular Rage Activation In Type 2 Diabetes.,Not Mentioned,Not Mentioned,2-4 Weeks,Secondary Endpoint
11,NCT03362762,Type 2 Diabetes Treated With Insulin,"Characteristic Of Type 2 Diabetes Patients, Treated With Insulin In Guadeloupe",Not Mentioned,Not Mentioned,"Trough Study Completion, An Average Of 2 Years",Primary Endpoint
12,NCT03362762,Type 2 Diabetes Treated With Insulin,Describe The Relation Between The Rate Of Hbac And The Plan Of Insulinothérapie,Not Mentioned,Not Mentioned,"Trough Study Completion, An Average Of 2 Years",Secondary Endpoint
13,NCT01920256,Type 2 Diabetes,Change In Baseline A1C (Glycated Hemoglobin) At 12 Months,Not Mentioned,Not Mentioned,12 Months,Primary Endpoint
14,NCT01920256,Type 2 Diabetes,Change In Baseline Lipids At 12 Months,Not Mentioned,Not Mentioned,12 Months,Secondary Endpoint
15,NCT01920256,Type 2 Diabetes,Change In Baseline Blood Pressure At 12 Months,Not Mentioned,Not Mentioned,12 Months,Secondary Endpoint
16,NCT01920256,Type 2 Diabetes,All Cause Mortality,Not Mentioned,Not Mentioned,12 Months,Secondary Endpoint
17,NCT01920256,Type 2 Diabetes,Acute Complications,Not Mentioned,Not Mentioned,12 Months,Secondary Endpoint
18,NCT01920256,Type 2 Diabetes,Change In Baseline Quality Of Life At 12 Months,Not Mentioned,Not Mentioned,12 Months,Secondary Endpoint
19,NCT01920256,Type 2 Diabetes,Change In Baseline Insulin Satisfaction At 12 Months,Not Mentioned,Not Mentioned,12 Months,Secondary Endpoint
20,NCT03840850,Type 2 Diabetes Mellitus,"Feasibility Of Implementing The Intervention In Primary Care: Binary Outcome (Feasible / Not Feasible), As Judged By The Investigators",Not Mentioned,Not Mentioned,3 Months,Primary Endpoint
21,NCT03840850,Type 2 Diabetes Mellitus,Recall Of Personalised Risk Information,Not Mentioned,Not Mentioned,3 Months,Secondary Endpoint
22,NCT03840850,Type 2 Diabetes Mellitus,Intentions To Make Lifestyle Changes,Not Mentioned,Not Mentioned,3 Months,Secondary Endpoint
23,NCT03840850,Type 2 Diabetes Mellitus,Change In Self-Management Behaviour,Not Mentioned,Not Mentioned,3 Months,Secondary Endpoint
24,NCT00392678,Type 2 Diabetes,Change In Hba1C Baseline To End Of Trial In Tinsal-T2D Stage 1,Not Mentioned,Not Mentioned,14 Week,Primary Endpoint
25,NCT00392678,Type 2 Diabetes,Change In Hba1C,Not Mentioned,Not Mentioned,14 Week,Secondary Endpoint
26,NCT00392678,Type 2 Diabetes,Change From Baseline And Trends In Fasting Glucose Over Time,Not Mentioned,Not Mentioned,14 Week,Secondary Endpoint
27,NCT00392678,Type 2 Diabetes,Change In Lipids,Not Mentioned,Not Mentioned,14 Week,Secondary Endpoint
28,NCT00392678,Type 2 Diabetes,"Change From Baseline In 14-Week Insulin, C-Peptide, Homeostasis Model [Homa] Index",Not Mentioned,Not Mentioned,"Baseline, Week 14",Secondary Endpoint
29,NCT00392678,Type 2 Diabetes,Safety And Tolerability,Not Mentioned,Not Mentioned,14 Weeks,Secondary Endpoint
30,NCT00392678,Type 2 Diabetes,"Change In Insulin, C-Peptide, Homeostasis Model [Homa] Index",Not Mentioned,Not Mentioned,"Baseline, Week 14",Secondary Endpoint
31,NCT03159221,"Diabetes Mellitus, Type 2|Childhood Obesity",Change In Body Mass Index (Weight Status) At 6 Months And At 12 Months,Not Mentioned,Not Mentioned,"Baseline, 6 Months After Baseline, 12 Months After Baseline",Primary Endpoint
32,NCT03159221,"Diabetes Mellitus, Type 2|Childhood Obesity",Metabolic Control (Hba1C),Not Mentioned,Not Mentioned,"Baseline, 6 Months After Baseline, 12 Months After Baseline",Secondary Endpoint
33,NCT03159221,"Diabetes Mellitus, Type 2|Childhood Obesity",Treatment Adherence,Not Mentioned,Not Mentioned,"Baseline, 6 Months After Baseline, 12 Months After Baseline",Secondary Endpoint
34,NCT03159221,"Diabetes Mellitus, Type 2|Childhood Obesity",Family Problem-Solving,Not Mentioned,Not Mentioned,"Baseline, 6 Month After Baseline",Secondary Endpoint
35,NCT03159221,"Diabetes Mellitus, Type 2|Childhood Obesity",Physical Activity,Not Mentioned,Not Mentioned,"Baseline, 6 Months After Baseline",Secondary Endpoint
36,NCT03159221,"Diabetes Mellitus, Type 2|Childhood Obesity",Body Fat (Weight Status),Not Mentioned,Not Mentioned,"Baseline, 6 Months After Baseline, 12 Months After Baseline",Secondary Endpoint
37,NCT03159221,"Diabetes Mellitus, Type 2|Childhood Obesity",Waist Circumference (Weight Status),Not Mentioned,Not Mentioned,"Baseline, 6 Months After Baseline, 12 Months After Baseline",Secondary Endpoint
38,NCT03159221,"Diabetes Mellitus, Type 2|Childhood Obesity",Food Intake,Not Mentioned,Not Mentioned,"Baseline, 6 Months After Baseline",Secondary Endpoint
39,NCT03159221,"Diabetes Mellitus, Type 2|Childhood Obesity",Family Communication Skills,Not Mentioned,Not Mentioned,"Baseline, 6 Months After Baseline",Secondary Endpoint
40,NCT03159221,"Diabetes Mellitus, Type 2|Childhood Obesity",Teen Self-Esteem,Not Mentioned,Not Mentioned,"Baseline, 6 Months After Baseline",Secondary Endpoint
41,NCT03159221,"Diabetes Mellitus, Type 2|Childhood Obesity",Teen Quality Of Life,Not Mentioned,Not Mentioned,"Baseline, 6 Months After Baseline",Secondary Endpoint
42,NCT00485758,Diabetes Mellitus Type 2,Percent Change At Week (Wk) 12 Compared To Baseline (Bl) In Low-Density Lipoprotein Cholesterol In Patients With Type 2 Diabetes When Compared To Placebo,Not Mentioned,Not Mentioned,Baseline And 12 Weeks,Primary Endpoint
43,NCT00485758,Diabetes Mellitus Type 2,Percent Change At Week (Wk) 12 Compared To Baseline (Bl) In High Density Lipoprotein Cholesterol In Patients With Type 2 Diabetes When Compared To Placebo,Not Mentioned,Not Mentioned,Baseline And 12 Weeks,Secondary Endpoint
44,NCT00485758,Diabetes Mellitus Type 2,Percent Change At Week (Wk) 12 Compared To Baseline (Bl) In Triglycerides In Patients With Type 2 Diabetes When Compared To Placebo,Not Mentioned,Not Mentioned,Baseline And 12 Weeks,Secondary Endpoint
45,NCT03044860,Type2 Diabetes,Evaluation Of Enteroendocrine Cells (Density And Mrna Expression) In The Intestinal Tract.,Not Mentioned,Not Mentioned,"Cross-Sectional Study. Each Participant Went Through Two Study Days (Upper And Lower Double-Ballon Enteroscopy, Respectively)",Primary Endpoint
46,NCT03044860,Type2 Diabetes,Evaluation Of Differences In Enteroendocrine Cells (Density And Mrna Expression) Along The Intestinal Tract Of Healthy Individuals Compared With Type 2 Diabetes Patients.,Not Mentioned,Not Mentioned,"Cross-Sectional Study. Each Participant Went Through Two Study Days (Upper And Lower Double-Ballon Enteroscopy, Respectively)",Primary Endpoint
47,NCT03044860,Type2 Diabetes,Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
48,NCT02355145,Type 2 Diabetes Mellitus,Change In The Frequency Of Usage By Physicians Of The Main Criteria For Selecting The Add-On Therapy In Patients With Inadequately Metformin-Controlled Type 2 Diabetes,Not Mentioned,Not Mentioned,From Moment 1 (Up To 2 Months From Fsi) To Moment 2 (1 Year After Moment 1),Primary Endpoint
49,NCT02355145,Type 2 Diabetes Mellitus,Number Of Years (Duration) Of Add-On Therapies In Type 2 Diabetes,Not Mentioned,Not Mentioned,In 2 Time Points At 1 Year Distance - Moment 1 (Up To 2 Months From Fsi) And Moment 2 (1 Year After Moment 1),Secondary Endpoint
50,NCT02355145,Type 2 Diabetes Mellitus,Percentage Of Subjects With Specific Comorbid Conditions And/Or Diabetes Complications,Not Mentioned,Not Mentioned,In 2 Time Points At 1 Year Distance - Moment 1 (Up To 2 Months From Fsi) And Moment 2 (1 Year After Moment 1),Secondary Endpoint
51,NCT02355145,Type 2 Diabetes Mellitus,Percentage Of Patients With Target Hba1C Level < 7% At The 2 Time-Points,Not Mentioned,Not Mentioned,In 2 Time Points At 1 Year Distance - Moment 1 (Up To 2 Months From Fsi) And Moment 2 (1 Year After Moment 1),Secondary Endpoint
52,NCT02355145,Type 2 Diabetes Mellitus,Number Of Years Of Type 2 Diabetes Disease Duration,Not Mentioned,Not Mentioned,In 2 Time Points At 1 Year Distance - Moment 1 (Up To 2 Months From Fsi) And Moment 2 (1 Year After Moment 1),Secondary Endpoint
53,NCT02355145,Type 2 Diabetes Mellitus,Frequency Of The Used Classes Of Drugs,Not Mentioned,Not Mentioned,In 2 Time Points At 1 Year Distance - Moment 1 (Up To 2 Months From Fsi) And Moment 2 (1 Year After Moment 1),Secondary Endpoint
54,NCT02355145,Type 2 Diabetes Mellitus,Number Of Years Until Starting The Add-On Therapies After Diagnosis,Not Mentioned,Not Mentioned,In 2 Time Points At 1 Year Distance - Moment 1 (Up To 2 Months From Fsi) And Moment 2 (1 Year After Moment 1),Secondary Endpoint
55,NCT01257087,Type 2 Diabetes Mellitus|Obesity,Percentage Of Patients With Type 2 Diabetes Mellitus Who Achieve Fasting Blood Glucose Of Less Than 5.6 Mmol/L And/Or Hba1C Of Less Than 6%,Not Mentioned,Not Mentioned,1 Year After Surgery,Primary Endpoint
56,NCT01257087,Type 2 Diabetes Mellitus|Obesity,Percentage Of Type 2 Diabetes Mellitus Patients With A Reduction In The Doses/Number Of Diabetes Medications Used Preoperatively,Not Mentioned,Not Mentioned,1 Year After Surgery,Secondary Endpoint
57,NCT01257087,Type 2 Diabetes Mellitus|Obesity,Number Of Participants With Microvascular Events,Not Mentioned,Not Mentioned,1 Year After Surgery,Secondary Endpoint
58,NCT03130894,Type2 Diabetes,Type 2 Diabetes,Not Mentioned,Not Mentioned,"Through Recruitment Completion, An Average Of 3 Years",Primary Endpoint
59,NCT03130894,Type2 Diabetes,Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
60,NCT02440555,Type 2 Diabetes,Sensitivity Of Detection Of Type 2 Diabetes,Not Mentioned,Not Mentioned,Day 1 (Inclusion Day),Primary Endpoint
61,NCT02440555,Type 2 Diabetes,Specificity Of Detection Of Type 2 Diabetes,Not Mentioned,Not Mentioned,Day 1 (Inclusion Day),Secondary Endpoint
62,NCT02440555,Type 2 Diabetes,To Evaluate The Cost Of The Targeted Screening And The Screening Accessibility To Population From The Priority Health Area Of Saint-Etienne,Not Mentioned,Not Mentioned,Month 2,Secondary Endpoint
63,NCT02440555,Type 2 Diabetes,To Evaluate The Numbers Of Patients Screened By Self-Administered Questionnaire And Diagnosed As Diabetics Using Fasting Glucose.,Not Mentioned,Not Mentioned,Month 2,Secondary Endpoint
64,NCT02327429,Type 2 Diabetes,Change In Energy Intake (3-Day Food Record),Not Mentioned,Not Mentioned,12 Weeks,Primary Endpoint
65,NCT02327429,Type 2 Diabetes,Change In Carbohydrate Intake (3-Day Food Record),Not Mentioned,Not Mentioned,12 Weeks,Primary Endpoint
66,NCT02327429,Type 2 Diabetes,Change In Protein Intake (3-Day Food Record),Not Mentioned,Not Mentioned,12 Weeks,Primary Endpoint
67,NCT02327429,Type 2 Diabetes,Change In Total Fat Intake (3-Day Food Record),Not Mentioned,Not Mentioned,12 Weeks,Primary Endpoint
68,NCT02327429,Type 2 Diabetes,Change In Saturated Fat Intake (3-Day Food Record),Not Mentioned,Not Mentioned,12 Weeks,Primary Endpoint
69,NCT02327429,Type 2 Diabetes,Change In Dietary Fibre Intake (3-Day Food Record),Not Mentioned,Not Mentioned,12 Weeks,Primary Endpoint
70,NCT02327429,Type 2 Diabetes,Change In Added Sucrose Intake (3-Day Food Record),Not Mentioned,Not Mentioned,12 Weeks,Primary Endpoint
71,NCT02327429,Type 2 Diabetes,Change In Sodium Intake (3-Day Food Record),Not Mentioned,Not Mentioned,12 Weeks,Primary Endpoint
72,NCT02327429,Type 2 Diabetes,Change In Calcium Intake (3-Day Food Record),Not Mentioned,Not Mentioned,12 Weeks,Primary Endpoint
73,NCT02327429,Type 2 Diabetes,Change In Cholesterol Intake (3-Day Food Record),Not Mentioned,Not Mentioned,12 Weeks,Primary Endpoint
74,NCT02327429,Type 2 Diabetes,Change In Hemoglobin A1C (A1C),Not Mentioned,Not Mentioned,12 Weeks,Secondary Endpoint
75,NCT02327429,Type 2 Diabetes,Change In Body Mass Index (Bmi),Not Mentioned,Not Mentioned,12 Weeks,Secondary Endpoint
76,NCT02327429,Type 2 Diabetes,Change In Waist Circumference,Not Mentioned,Not Mentioned,12 Weeks,Secondary Endpoint
77,NCT02327429,Type 2 Diabetes,Change In Fasting Triglyceride,Not Mentioned,Not Mentioned,12 Weeks,Secondary Endpoint
78,NCT02327429,Type 2 Diabetes,Change In Fasting Total Cholesterol,Not Mentioned,Not Mentioned,12 Weeks,Secondary Endpoint
79,NCT02327429,Type 2 Diabetes,Change In Fasting Low-Density Lipoprotein Cholesterol,Not Mentioned,Not Mentioned,12 Weeks,Secondary Endpoint
80,NCT02327429,Type 2 Diabetes,Change In Fasting High-Density Lipoprotein Cholesterol,Not Mentioned,Not Mentioned,12 Weeks,Secondary Endpoint
81,NCT03259321,Type2 Diabetes,Type 2 Diabetes,Not Mentioned,Not Mentioned,From Entry Into The Study (Baseline: 1997-2009) Until 2011,Primary Endpoint
82,NCT03259321,Type2 Diabetes,Fish And Polyunsaturated Fatty Acids Intake,Not Mentioned,Not Mentioned,From Entry Into The Study (Baseline: 1997-2009) Until 2011,Secondary Endpoint
83,NCT04016584,Type2 Diabetes,"Success (Evaluated By A Yes/No Format) Recruiting And Completing A New Targeted Diabetes And Insulin Education Program, Diabetes Pueblo, For Latino Adults With Type 2 Diabetes.",Not Mentioned,Not Mentioned,11 Weeks,Primary Endpoint
84,NCT04016584,Type2 Diabetes,Diabetes Self Management Evaluated By Questionnaire,Not Mentioned,Not Mentioned,"Visit 1, Week 0 Screening; Visit 2, Week 8 End Of Diabetes Fundamentals Class",Secondary Endpoint
85,NCT04016584,Type2 Diabetes,Insulin Treatment Evaluated By Questionnaire,Not Mentioned,Not Mentioned,"Visit 1, Week 0 Screening; Visit 2, Week 8 End Of Diabetes Fundamentals Class; Visit 3, Week 11 End Of Insulin Success Class",Secondary Endpoint
86,NCT04016584,Type2 Diabetes,Participant Evaluation Of Diabetes Pueblo Evaluated By Questionnaire,Not Mentioned,Not Mentioned,"Class 4, Week 4; Class 8, Week 8; Class 10, Week 10",Secondary Endpoint
87,NCT04016584,Type2 Diabetes,Participant Evaluation Of Diabetes Pueblo Evaluated By Questionnaire,Not Mentioned,Not Mentioned,"Class 11, Week 11",Secondary Endpoint
88,NCT00810823,Type 2 Diabetes,"What Is The Factor ""X"" That Cause The Remission Of Type 2 Diabetes After Gastric Bypass",Not Mentioned,Not Mentioned,About 3 Years,Primary Endpoint
89,NCT00810823,Type 2 Diabetes,Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
90,NCT01601574,Type 2 Diabetes|Overweight|Obesity,Change In Hba1C,Not Mentioned,Not Mentioned,Baseline And 12 Months,Primary Endpoint
91,NCT01601574,Type 2 Diabetes|Overweight|Obesity,Secondary Endpoints,Not Mentioned,Not Mentioned,Baseline And 12 Months,Secondary Endpoint
92,NCT01601574,Type 2 Diabetes|Overweight|Obesity,Secondary Endpoints,Not Mentioned,Not Mentioned,Baseline And 12 Months,Secondary Endpoint
93,NCT01601574,Type 2 Diabetes|Overweight|Obesity,Secondary Endpoints,Not Mentioned,Not Mentioned,Baseline And 12 Months,Secondary Endpoint
94,NCT01601574,Type 2 Diabetes|Overweight|Obesity,Secondary Endpoints,Not Mentioned,Not Mentioned,Baseline And 12 Months,Secondary Endpoint
95,NCT01601574,Type 2 Diabetes|Overweight|Obesity,Secondary Endpoints,Not Mentioned,Not Mentioned,Baseline And 12 Months,Secondary Endpoint
96,NCT01601574,Type 2 Diabetes|Overweight|Obesity,Secondary Endpoints,Not Mentioned,Not Mentioned,Baseline And 12 Months,Secondary Endpoint
97,NCT01601574,Type 2 Diabetes|Overweight|Obesity,Secondary Endpoints,Not Mentioned,Not Mentioned,Baseline And 12 Months,Secondary Endpoint
98,NCT01601574,Type 2 Diabetes|Overweight|Obesity,Secondary Endpoints,Not Mentioned,Not Mentioned,Baseline And 12 Months,Secondary Endpoint
99,NCT03243136,Type2 Diabetes,Type 2 Diabetes,Not Mentioned,Not Mentioned,2004-2016,Primary Endpoint
100,NCT03243136,Type2 Diabetes,Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
101,NCT01021865,Coronary Artery Disease|Diabetes Mellitus Type 2,To Determine Whether Hyperglycemia Alters Myocardial Perfusion In Subjects With Type 2 Diabetes,Not Mentioned,Not Mentioned,Nov 2009-2011,Primary Endpoint
102,NCT01021865,Coronary Artery Disease|Diabetes Mellitus Type 2,To Determine Whether Glp-1 Modulates Myocardial Perfusion In Subjects With Type 2 Diabetes.,Not Mentioned,Not Mentioned,Nov 2009-2011,Secondary Endpoint
103,NCT01055652,Type 2 Diabetes Mellitus,To Evaluate The Pharmacokinetics Of Dapagliflozin When Administered Alone Or In Combination With Voglibose In Japanese Patients With Type 2 Diabetes By Assessment Of Auc And Cmax Of Dapagliflozin,Not Mentioned,Not Mentioned,Plasma Samples Will Be Collected Through Visit 4 (Up To 72 Hours = 3 Days After Dose) For Pk Assessment For Period 1. Plasma Samples Will Be Collected Through Visit 7 (Up To 72 Hours = 3 Days After Dose) For Pk Assessment For Period 2.,Primary Endpoint
104,NCT01055652,Type 2 Diabetes Mellitus,To Evaluate The Safety And Tolerability Of Dapagliflozin When Administered Alone Or In Combi-Nation With Voglibose In Japanese Patients With Type 2 Diabetes.,Not Mentioned,Not Mentioned,Plasma Samples Will Be Collected Through Visit 4 (Up To 72 Hours = 3 Days After Dose) For Pk Assessment For Period 1. Plasma Samples Will Be Collected Through Visit 7 (Up To 72 Hours = 3 Days After Dose) For Pk Assessment For Period 2.,Secondary Endpoint
105,NCT01055652,Type 2 Diabetes Mellitus,"To Evaluate The Pharmacokinetics Of Dapagliflozin When Administered Alone Or In Combination With Voglibose In Japanese Patients With Type 2 Diabetes By Assessmentof Auc0-T, Tmax, T1/2, Cl/F.",Not Mentioned,Not Mentioned,Plasma Samples Will Be Collected Through Visit 4 (Up To 72 Hours = 3 Days After Dose) For Pk Assessment For Period 1. Plasma Samples Will Be Collected Through Visit 7 (Up To 72 Hours = 3 Days After Dose) For Pk Assessment For Period 2.,Secondary Endpoint
106,NCT02290860,"Diabetes, Gestational",Abnormal Glucose Tolerance,Not Mentioned,Not Mentioned,8 Weeks After Delivery,Primary Endpoint
107,NCT02290860,"Diabetes, Gestational",Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
108,NCT04005261,Type 2 Diabetes Treated With Insulin,"The Incidence Of Adequate, Borderline And Insufficient Beta Cell Reserves Assessed By The Fasting C-Peptide Concentrations",Not Mentioned,Not Mentioned,3 Months,Primary Endpoint
109,NCT04005261,Type 2 Diabetes Treated With Insulin,Correlations Of Fasting C-Peptide Concentrations With Patients Characteristics And Biochemical Findings,Not Mentioned,Not Mentioned,3 Months,Primary Endpoint
110,NCT04005261,Type 2 Diabetes Treated With Insulin,Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
111,NCT00612794,Type 2 Diabetes,To Assess The Safety And Tolerability Of Exenatide Administered Once Weekly By Subcutaneous (Sc) Injection In Subjects With Type 2 Diabetes Mellitus.,Not Mentioned,Not Mentioned,10 Weeks,Primary Endpoint
112,NCT00612794,Type 2 Diabetes,To Assess The Pharmacokinetics Of Exenatide Administered Once Weekly By Sc Injection In Subjects With Type 2 Diabetes Mellitus.,Not Mentioned,Not Mentioned,10 Weeks,Secondary Endpoint
113,NCT00612794,Type 2 Diabetes,To Explore The Pharmacodynamics Of Exenatide Administered Once Weekly By Sc Injection In Subjects With Type 2 Diabetes Mellitus Regarding The Following: *Fasting And Postprandial Glucose Concentrations; *Hba1C; *Body Weight.,Not Mentioned,Not Mentioned,10 Weeks,Secondary Endpoint
114,NCT01727349,Type 2 Diabetes,Measure Of Risk Of Developing Type 2 Diabetes In At-Risk Families,Not Mentioned,Not Mentioned,"Participants Will Be Followed From The Moment Where They Sign Consent Form And Until They Have Sent Back Questionnary And Done The Blood Test, An Expected Average Of 4 Weeks",Primary Endpoint
115,NCT01727349,Type 2 Diabetes,Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
116,NCT00239187,Type 2 Diabetes,To Assess The Safety And Tolerability Of Repeated Subcutaneous Doses Of E1 In Combination With G1 In Patients With Type 2 Diabetes,Not Mentioned,Not Mentioned,Nan,Primary Endpoint
117,NCT00239187,Type 2 Diabetes,To Evaluate The Pharmacokinetics (Pk) Profile And Clinical Effects Of Repeated Subcutaneous Doses Of E1 In Combination With G1 In Patients With Type 2 Diabetes,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
118,NCT01073020,Type 2 Diabetes Mellitus|Obesity,Fasting Plasma Glucose <126 Mg/Dl And Hba1C < 6.5% At Three Years Of Follow-Up.,Not Mentioned,Not Mentioned,3 Years,Primary Endpoint
119,NCT01073020,Type 2 Diabetes Mellitus|Obesity,"Glycemic Control, As Measured By Hemoglobin A1C",Not Mentioned,Not Mentioned,3 Years,Secondary Endpoint
120,NCT01073020,Type 2 Diabetes Mellitus|Obesity,Body Mass Index,Not Mentioned,Not Mentioned,3 Years,Secondary Endpoint
121,NCT01073020,Type 2 Diabetes Mellitus|Obesity,Cardiovascular Risk,Not Mentioned,Not Mentioned,3 Years,Secondary Endpoint
122,NCT01249677,Type 2 Diabetes,Improvements In First And Second Phase Insulin Secretion,Not Mentioned,Not Mentioned,8 Weeks,Primary Endpoint
123,NCT01249677,Type 2 Diabetes,Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
124,NCT01085292,Type 2 Diabetes Mellitus,Safety And Tolerability Of Multiple Intravenous Doses Of Nox-E36 In Healthy Subjects And Patients With Type Ii Diabetes Mellitus,Not Mentioned,Not Mentioned,4 Weeks,Primary Endpoint
125,NCT01085292,Type 2 Diabetes Mellitus,Multiple Dose Pharmacokinetics And Pharmacodynamics Of Nox-E36 In Healthy Subjects And Patients With Type Ii Diabetes Mellitus,Not Mentioned,Not Mentioned,4 Weeks,Secondary Endpoint
126,NCT01182935,Type 2 Diabetes,Number Of Subjects With Type 2 Diabetes Diagnosed With Oral Glucose Tolerance Test (Ogtt),Not Mentioned,Not Mentioned,At Study Enrollment In 2010,Primary Endpoint
127,NCT01182935,Type 2 Diabetes,The Relation Between Serum 25(Oh)D Levels And Blood Glucose Levels At Ogtt,Not Mentioned,Not Mentioned,At Study Enrollment In 2010,Secondary Endpoint
128,NCT02205996,Type 2 Diabetes Mellitus,To Examine The Effect Of Hypoglycaemia On Platelet Surface Expression Of Platelet Activation Markers P-Selectin And Fibrinogen Binding.,Not Mentioned,Not Mentioned,Up To 24 Hours After Euglycaemic Hypoglycaemic Clamp,Primary Endpoint
129,NCT02205996,Type 2 Diabetes Mellitus,To Measure Changes In Markers Of Inflammation (High Sensitivity C-Reactive Protein) And Endothelial Function Using Endopat 2000,Not Mentioned,Not Mentioned,Up To 24H After Euglycaemic Hypoglycaemic Clamp,Secondary Endpoint
130,NCT00240253,Type 2 Diabetes Mellitus,To Evaluate The Efficacy And Safety Of Adding Symlin To An Established Regimen Of Insulin Glargine In Subjects With Type 2 Diabetes.,Not Mentioned,Not Mentioned,16 Weeks,Primary Endpoint
131,NCT00240253,Type 2 Diabetes Mellitus,"To Evaluate The Effects Of Adding Symlin To An Established Regimen Of Insulin Glargine In Subjects With Type 2 Diabetes On Markers Of Cardiovascular Risk, Fasting Serum Lipids, Fasting Plasma Glucose, Waist Circumference, And Patient-Reported Outcomes.",Not Mentioned,Not Mentioned,16 Weeks,Secondary Endpoint
132,NCT00982371,Type 2 Diabetes Mellitus,"1 Tesla Peripheral Mri Assessment At Non Dominant Distal Radius: Trabecular Bone Micro-Architecture Parameters Tb.Th, Tb.Sp, Tb.N, Bv/Tv, Bone Csa, Marrow Space",Not Mentioned,Not Mentioned,Mri Scan Complete Approximately 1 Month After Participant Is Enrolled,Primary Endpoint
133,NCT00982371,Type 2 Diabetes Mellitus,"Calcium, Vitamin D And Vitamin K Dietary Intakes; Tug (Sec); Grip Strength; Dxa Assessment Of Hip, Lumbar Spine, Total Body; Physical Activity",Not Mentioned,Not Mentioned,Baseline,Secondary Endpoint
134,NCT04031417,Type 2 Diabetes,Hypoxia And Low Humidity On The Endothelial Function In Healthy Volunteers And Patients With Type 2 Diabetes Using Wilcoxon Signed Rank Test,Not Mentioned,Not Mentioned,Change From Baseline To 2 Hours,Primary Endpoint
135,NCT04031417,Type 2 Diabetes,Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
136,NCT01284465,Type 2 Diabetes,Hba1C,Not Mentioned,Not Mentioned,"Baseline, 6 And 12 Months",Primary Endpoint
137,NCT01284465,Type 2 Diabetes,Risk Factors For Co-Morbidity And Daily Self-Management Behaviors,Not Mentioned,Not Mentioned,"Baseline, 3, 6, 9 And 12 Months",Secondary Endpoint
138,NCT02226822,Type 2 Diabetes Mellitus,Classes Of Diabetic Medications At Baseline And Changes Up To 3 Years,Not Mentioned,Not Mentioned,"At 6, 12, 24, 36 Month From Enrollment",Primary Endpoint
139,NCT02226822,Type 2 Diabetes Mellitus,"Hemoglobin A1C Change From Baseline, Achievement Rate Of Hba1C And Blood Glucose Target Goals",Not Mentioned,Not Mentioned,"At 6, 12, 24, 36 Month From Enrollment",Secondary Endpoint
140,NCT02226822,Type 2 Diabetes Mellitus,Blood Glucose Level Change From Baseline,Not Mentioned,Not Mentioned,"At 6, 12, 24, 36 Month From Enrollment",Secondary Endpoint
141,NCT02226822,Type 2 Diabetes Mellitus,Body Weight Change From Baseline,Not Mentioned,Not Mentioned,"At 6, 12, 24, 36 Month From Enrollment",Secondary Endpoint
142,NCT02226822,Type 2 Diabetes Mellitus,Blood Pressure Change From Baseline,Not Mentioned,Not Mentioned,"At 6, 12, 24, 36 Month From Enrollment",Secondary Endpoint
143,NCT02226822,Type 2 Diabetes Mellitus,Lipid Profile Changes From Baseline,Not Mentioned,Not Mentioned,"At 6, 12, 24, 36 Month From Enrollment",Secondary Endpoint
144,NCT02226822,Type 2 Diabetes Mellitus,Incidence Of Microvascular Complications,Not Mentioned,Not Mentioned,"At 6, 12, 24, 36 Month From Enrollment",Secondary Endpoint
145,NCT02226822,Type 2 Diabetes Mellitus,Hypoglycemia Events,Not Mentioned,Not Mentioned,"At 6, 12, 24, 36 Month From Enrollment",Secondary Endpoint
146,NCT02226822,Type 2 Diabetes Mellitus,"Patient Reported Quality Of Life, Diet, And Physical Activity Level",Not Mentioned,Not Mentioned,"At 6, 12, 24, 36 Month From Enrollment",Secondary Endpoint
147,NCT02226822,Type 2 Diabetes Mellitus,"Initiation Of Insulin Therapy, Proportion Of Patients Using Insulin",Not Mentioned,Not Mentioned,"At 6, 12, 24, 36 Month From Enrollment",Secondary Endpoint
148,NCT02226822,Type 2 Diabetes Mellitus,Switching Of Anti-Diabetic Medications Or Dose Change,Not Mentioned,Not Mentioned,"At 6, 12, 24, 36 Month From Enrollment",Secondary Endpoint
149,NCT02226822,Type 2 Diabetes Mellitus,Initiation Of Third Line Or Above Add-On Anti-Diabetic Medications,Not Mentioned,Not Mentioned,"At 6, 12, 24, 36 Month From Enrollment",Secondary Endpoint
150,NCT02226822,Type 2 Diabetes Mellitus,Incidence Of Macrovascular Complications,Not Mentioned,Not Mentioned,"At 6, 12, 24, 36 Month From Enrollment",Secondary Endpoint
151,NCT02226822,Type 2 Diabetes Mellitus,Risk Factors,Not Mentioned,Not Mentioned,"At 6, 12, 24, 36 Month After Enrollment",Secondary Endpoint
152,NCT02226822,Type 2 Diabetes Mellitus,Treatment Choice,Not Mentioned,Not Mentioned,At Baseline,Secondary Endpoint
153,NCT01869608,Type 2 Diabetes,Diagnosis Of Abnormal Glucose Tolerance,Not Mentioned,Not Mentioned,12 Weeks Postpartum,Primary Endpoint
154,NCT01869608,Type 2 Diabetes,Patient'S Satisfaction,Not Mentioned,Not Mentioned,12 Weeks Post-Partum,Secondary Endpoint
155,NCT01184768,Type 2 Diabetes,Number Of Subjects With New Diagnosis Of Type 2 Diabetes,Not Mentioned,Not Mentioned,Up To 2 Years After Participation In The 6Th Tromso Study,Primary Endpoint
156,NCT01184768,Type 2 Diabetes,Number Of Subjects With New Diagnosis Of Impaired Glucose Tolerance,Not Mentioned,Not Mentioned,Up To 2 Years After Participation In The 6Th Tromso Study,Secondary Endpoint
157,NCT01184768,Type 2 Diabetes,Number Of Subjects With New Diagnosis Of Impaired Fasting Glucose,Not Mentioned,Not Mentioned,Up To 2 Years After Participation In The 6Th Tromso Study,Secondary Endpoint
158,NCT01184768,Type 2 Diabetes,Effect Of Vitamin D Status On Glucose Tolerance,Not Mentioned,Not Mentioned,Up To 2 Years After Participation In The 6Th Tromso Study,Secondary Endpoint
159,NCT04501991,Type 2 Diabetes|Metabolic Control,Glucose,Not Mentioned,Not Mentioned,One Week After The End Of The Lockdown Period,Primary Endpoint
160,NCT04501991,Type 2 Diabetes|Metabolic Control,Hba1C,Not Mentioned,Not Mentioned,One Week After The End Of The Lockdown Period,Primary Endpoint
161,NCT04501991,Type 2 Diabetes|Metabolic Control,Lipid Profile,Not Mentioned,Not Mentioned,One Week After The End Of The Lockdown Period,Primary Endpoint
162,NCT04501991,Type 2 Diabetes|Metabolic Control,Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
163,NCT01010035,Type 2 Diabetes Mellitus,To Identify The Removal Of The Free And Esterified Cholesterol In Type 2 Diabetes Patients,Not Mentioned,Not Mentioned,Day Of Test,Primary Endpoint
164,NCT01010035,Type 2 Diabetes Mellitus,Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
165,NCT01387984,Type 2 Diabetes Mellitus,Nan,Not Mentioned,Not Mentioned,Nan,Primary Endpoint
166,NCT01387984,Type 2 Diabetes Mellitus,Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
167,NCT01237301,Type 2 Diabetes,Percentage Change In Hemoglobin A1C,Not Mentioned,Not Mentioned,2 Week Baseline To 16 Week Final,Primary Endpoint
168,NCT01237301,Type 2 Diabetes,Glucose Exposure (Area Under The Diurnal Median Curve),Not Mentioned,Not Mentioned,16 Weeks,Secondary Endpoint
169,NCT01237301,Type 2 Diabetes,Percent Of Time In Hypoglycemia Range,Not Mentioned,Not Mentioned,16 Weeks,Secondary Endpoint
170,NCT01237301,Type 2 Diabetes,Change From Baseline In Cgm Glucose Variability,Not Mentioned,Not Mentioned,Baseline And 16 Weeks,Secondary Endpoint
171,NCT04403841,Type 2 Diabetes,Disease Awareness,Not Mentioned,Not Mentioned,3-Month,Primary Endpoint
172,NCT04403841,Type 2 Diabetes,Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
173,NCT01088711,Type 2 Diabetes (T2D),Number Of Participants Experiencing An Adverse Event (Ae),Not Mentioned,Not Mentioned,Up To Day 36,Primary Endpoint
174,NCT01088711,Type 2 Diabetes (T2D),Number Of Participants Withdrawing From Study Therapy Due To An Ae,Not Mentioned,Not Mentioned,Up To Day 22,Primary Endpoint
175,NCT01088711,Type 2 Diabetes (T2D),Percent Inhibition Of Dipeptidyl Peptidase-4 (Dpp-4) After Day 15,Not Mentioned,Not Mentioned,168 Hours Post-Dose On Day 15,Secondary Endpoint
176,NCT01088711,Type 2 Diabetes (T2D),Percent Inhibition Of Dpp-4 After Day 22,Not Mentioned,Not Mentioned,168 Hours Post Dose On Day 22,Secondary Endpoint
177,NCT01088711,Type 2 Diabetes (T2D),Waa Active Glucagon-Like Peptide-1 (Glp-1) Concentration,Not Mentioned,Not Mentioned,Through 4 Hours Post Dose On Day 21,Secondary Endpoint
178,NCT01088711,Type 2 Diabetes (T2D),Waa Total Glp-1 Concentration,Not Mentioned,Not Mentioned,Through 4 Hours Post Dose On Day 21,Secondary Endpoint
179,NCT01088711,Type 2 Diabetes (T2D),Plasma Glucose Concentration,Not Mentioned,Not Mentioned,Through 4 Hours Post Dose On Day 21,Secondary Endpoint
180,NCT03214380,Type 2 Diabetes Mellitus,Change From Baseline In Hemoglobin A1C (Hba1C) Efficacy Estimand At Week 26,Not Mentioned,Not Mentioned,"Baseline, Week 26",Primary Endpoint
181,NCT03214380,Type 2 Diabetes Mellitus,1-Hour Postprandial Glucose (Ppg) Excursion During Mixed-Meal Tolerance Test (Mmtt) Efficacy Estimand,Not Mentioned,Not Mentioned,Week 26,Secondary Endpoint
182,NCT03214380,Type 2 Diabetes Mellitus,2-Hour Ppg Excursion During Mmtt Efficacy Estimand,Not Mentioned,Not Mentioned,Week 26,Secondary Endpoint
183,NCT03214380,Type 2 Diabetes Mellitus,Rate Of Severe Hypoglycemia,Not Mentioned,Not Mentioned,Baseline Through Week 26,Secondary Endpoint
184,NCT03214380,Type 2 Diabetes Mellitus,Rate Of Documented Symptomatic Hypoglycemia,Not Mentioned,Not Mentioned,Baseline Through Week 26,Secondary Endpoint
185,NCT03214380,Type 2 Diabetes Mellitus,"Change From Baseline In 1,5-Anhydroglucitol (1,5-Ag) At Week 26",Not Mentioned,Not Mentioned,"Baseline, Week 26",Secondary Endpoint
186,NCT03214380,Type 2 Diabetes Mellitus,Change From Baseline In 10-Point Self-Monitoring Blood Glucose (Smbg) Values At Week 26,Not Mentioned,Not Mentioned,"Baseline, Week 26",Secondary Endpoint
187,NCT03214380,Type 2 Diabetes Mellitus,Change From Baseline In Insulin Dose At Week 26,Not Mentioned,Not Mentioned,"Baseline, Week 26",Secondary Endpoint
188,NCT03214380,Type 2 Diabetes Mellitus,Change From Baseline In Insulin Treatment Satisfaction Questionnaire (Itsq) Regimen Inconvenience Domain Score At Week 26,Not Mentioned,Not Mentioned,"Baseline, Week 26",Secondary Endpoint
189,NCT03214380,Type 2 Diabetes Mellitus,Change From Baseline In Itsq Lifestyle Flexibility Domain Score At Week 26,Not Mentioned,Not Mentioned,"Baseline, Week 26",Secondary Endpoint
190,NCT03214380,Type 2 Diabetes Mellitus,Number Of Participants With Hba1C <7%,Not Mentioned,Not Mentioned,Week 26,Secondary Endpoint
191,NCT02322762,Type 2 Diabetes Mellitus,Anti-Diabetic Treatments Prescribed By Physicians In A Real-World Setting.,Not Mentioned,Not Mentioned,Up To 3 Years,Primary Endpoint
192,NCT02322762,Type 2 Diabetes Mellitus,Disease Control In Terms Of Achieving Hba1C Target Goals And Reducing Body Weight And Blood Pressure.,Not Mentioned,Not Mentioned,Up To 3 Years,Secondary Endpoint
193,NCT02322762,Type 2 Diabetes Mellitus,Changes In Anti-Diabetic Treatments,Not Mentioned,Not Mentioned,Up To 3 Years,Secondary Endpoint
194,NCT02322762,Type 2 Diabetes Mellitus,Disease Progression (Incidence Of Microvascular And Macrovascular Complications).,Not Mentioned,Not Mentioned,Up To 3 Years,Secondary Endpoint
195,NCT02322762,Type 2 Diabetes Mellitus,Incidence Of Hypoglycemic Events.,Not Mentioned,Not Mentioned,Up To 3 Years,Secondary Endpoint
196,NCT02322762,Type 2 Diabetes Mellitus,"Quality Of Life, Using Patient Reported Outcomes Questionnaires.",Not Mentioned,Not Mentioned,Up To 3 Years,Secondary Endpoint
197,NCT02322762,Type 2 Diabetes Mellitus,Use Of Healthcare Resources.,Not Mentioned,Not Mentioned,Up To 3 Years,Secondary Endpoint
198,NCT00888836,Type 2 Diabetes,"To Assess The Efficacy Of Bariatric Surgery In Inducing Partial Or Total Remission Of Type 2 Diabetes Mellitus, As Compared To Standard Medical Anti-Diabetic Care (Stc).",Not Mentioned,Not Mentioned,10 Years,Primary Endpoint
199,NCT00888836,Type 2 Diabetes,"Secondary Endpoints Include Percentage Change Of Fasting Plasma Glucose Levels, Glycated Hemoglobin, Weight, Waist Circumference, Blood Pressure, Cholesterol, Hdl-Cholesterol And Triglycerides, Hard Cardiovascular Risk And Quality Of Life.",Not Mentioned,Not Mentioned,10 Years,Secondary Endpoint
200,NCT03447275,"Diabetes Mellitus, Type 2|Vitamin B 12 Deficiency|Vitamin B 6 Deficiency",The Difference In Serum Vitamin B12 Levels Between Cases And Controls,Not Mentioned,Not Mentioned,Baseline,Primary Endpoint
201,NCT03447275,"Diabetes Mellitus, Type 2|Vitamin B 12 Deficiency|Vitamin B 6 Deficiency",The Difference In Serum Vitamin B1 Between Cases And Controls,Not Mentioned,Not Mentioned,Baseline,Primary Endpoint
202,NCT03447275,"Diabetes Mellitus, Type 2|Vitamin B 12 Deficiency|Vitamin B 6 Deficiency",The Difference In Serum Vitamin B6 Concentrations Between Cases And Controls,Not Mentioned,Not Mentioned,Baseline,Primary Endpoint
203,NCT03447275,"Diabetes Mellitus, Type 2|Vitamin B 12 Deficiency|Vitamin B 6 Deficiency",The Difference In Serum Vitamin B12 Between Patients With And Those Without Albuminuria,Not Mentioned,Not Mentioned,Baseline,Secondary Endpoint
204,NCT03447275,"Diabetes Mellitus, Type 2|Vitamin B 12 Deficiency|Vitamin B 6 Deficiency",The Difference In Serum And Urine Vitamin B1 Between Patients With And Those Without Albuminuria,Not Mentioned,Not Mentioned,Baseline,Secondary Endpoint
205,NCT03447275,"Diabetes Mellitus, Type 2|Vitamin B 12 Deficiency|Vitamin B 6 Deficiency",The Difference In Serum And Urine Vitamin B6 Vitamers Between Patients With And Those Without Albuminuria,Not Mentioned,Not Mentioned,Baseline,Secondary Endpoint
206,NCT03447275,"Diabetes Mellitus, Type 2|Vitamin B 12 Deficiency|Vitamin B 6 Deficiency",The Difference In Serum And Urine Vitamin B6 Vitamers Between Patients With Advanced Global Vascular Risk Versus Those With A Low Vascular Risk,Not Mentioned,Not Mentioned,Baseline,Secondary Endpoint
207,NCT00451620,Type 2 Diabetes,The Objective Of This Study Is To Determine Whether Gluconorm Has A Greater Effect Than Glyburide On Insulin Levels And Postprandial Glucose Levels In Elderly People With Type 2 Diabetes Who Are Diet Controlled.,Not Mentioned,Not Mentioned,2 Hours,Primary Endpoint
208,NCT00451620,Type 2 Diabetes,Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
209,NCT01845064,Diabetes Type 2,Safety And Tolerability Of Single And Multiple Subcutaneous Doses Of Dm199,Not Mentioned,Not Mentioned,Up To 13 Days After Final Dose,Primary Endpoint
210,NCT01845064,Diabetes Type 2,Determine The Pharmacokinetic Of Dm199 After Single And Multiple Doses,Not Mentioned,Not Mentioned,Up To 3 Days After Final Dose,Primary Endpoint
211,NCT01845064,Diabetes Type 2,Determine The Effect Of Dm199 On Glucose Homeostasis In Healthy Volunteers And Type 2 Diabetes Mellitus Patients,Not Mentioned,Not Mentioned,"Part C, Day -1 And 14; Part D, Days -1, 14 And 28",Secondary Endpoint
212,NCT01845064,Diabetes Type 2,Assess Formation Of Ada To Dm199,Not Mentioned,Not Mentioned,"Part C, Day -1 And 42; Part D, Day -1 And 35",Secondary Endpoint
213,NCT01845064,Diabetes Type 2,Determine Changes In Immune Cell Populations By Facs Analysis.,Not Mentioned,Not Mentioned,"Part C, Day -1 And 15; Part D, Day -1 And 29",Secondary Endpoint
214,NCT02104804,Type 2 Diabetes Mellitus,Change In Hba1C From Baseline To Week 24,Not Mentioned,Not Mentioned,Baseline To 24 Weeks,Primary Endpoint
215,NCT02104804,Type 2 Diabetes Mellitus,Change In Postprandial Glucose Auc From Baseline To Week 24 During A Meal Tolerance Test,Not Mentioned,Not Mentioned,Baseline To 24 Weeks,Secondary Endpoint
216,NCT02104804,Type 2 Diabetes Mellitus,Analysis Of Change In 120-Minute Ppg From Baseline To Week 24 During A Meal Tolerance Test,Not Mentioned,Not Mentioned,Baseline To 24 Weeks,Secondary Endpoint
217,NCT02104804,Type 2 Diabetes Mellitus,Percentage Of Patients Achieving A Therapeutic Glycaemic Response Of Hba1C <7%,Not Mentioned,Not Mentioned,At Week 24,Secondary Endpoint
218,NCT02104804,Type 2 Diabetes Mellitus,The Analysis Of Change In Fasting Plasma Glucose From Baseline To Week 24 (This Was The Average Of Weeks 20 And 24),Not Mentioned,Not Mentioned,Baseline To Average Of Weeks 20 And 24,Secondary Endpoint
219,NCT02104804,Type 2 Diabetes Mellitus,Analysis Of Change In Mean Total Daily Dose Of Insulin From Baseline To Week 24,Not Mentioned,Not Mentioned,Baseline To 24 Weeks,Secondary Endpoint
220,NCT00787670,Obesity|Type 2 Diabetes Mellitus,To Determine Whether Surgically Induced Weight Loss Decreases The Risk Of Cvd In Morbidly Obese Subjects With Type 2 Diabetes Mellitus (T2Dm),Not Mentioned,Not Mentioned,"0, 6, 12 Months",Primary Endpoint
221,NCT00787670,Obesity|Type 2 Diabetes Mellitus,To Elucidate The Mechanisms By Which Surgically Induced Weight Loss Reduces Over Time The Risk Of Cvd In Morbidly Obese Subjects With T2Dm.,Not Mentioned,Not Mentioned,"0, 6, 12 Months",Secondary Endpoint
222,NCT01933256,Type 2 Diabetes Mellitus,The Safety And Tolerability Of Repeat Doses Of Hip2B In Subjects With Type 2 Diabetes Mellitus.,Not Mentioned,Not Mentioned,Adverse Events / Vitals Are Monitored At Each Study Visit Between Days -9 And 84.,Primary Endpoint
223,NCT01933256,Type 2 Diabetes Mellitus,Glucose-Stimulated Insulin Secretion.,Not Mentioned,Not Mentioned,"Ivgtt Performed On Day -8 And Day 49. Ggi Performed On Day -1, Day 25 And Day 46.",Secondary Endpoint
224,NCT03406910,Type 2 Diabetes|Heart Diseases,Risk For Type 2 Diabetes (T2D) In Subjects Who Consume Different Frequencies/Amounts Of Eggs And Meat.,Not Mentioned,Not Mentioned,Change Between Baseline And 5 Years Of Follow Up,Primary Endpoint
225,NCT03406910,Type 2 Diabetes|Heart Diseases,Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
226,NCT01649466,Type 2 Diabetes Mellitus,Percentage Of Patients Reaching Hba1C Below 7.0% Without Confirmed Hypoglycemia And Weight Gain,Not Mentioned,Not Mentioned,24 Weeks,Primary Endpoint
227,NCT01649466,Type 2 Diabetes Mellitus,Rate Of Confirmed Hypoglycemic Events,Not Mentioned,Not Mentioned,24 Weeks,Primary Endpoint
228,NCT01649466,Type 2 Diabetes Mellitus,Incidence Of Severe Hypoglycemic Events,Not Mentioned,Not Mentioned,24 Weeks,Secondary Endpoint
229,NCT01649466,Type 2 Diabetes Mellitus,Incidence Of Symptomatic Hypoglycemic Events,Not Mentioned,Not Mentioned,24 Weeks,Secondary Endpoint
230,NCT01649466,Type 2 Diabetes Mellitus,Percentage Of Patients Who Reach Their Blood Glucose Target (Hba1C Below 7.0%) Without Any Confirmed Hypoglycemic Event,Not Mentioned,Not Mentioned,24 Weeks,Secondary Endpoint
231,NCT01649466,Type 2 Diabetes Mellitus,Change From Baseline In Body Weight At 24 Weeks,Not Mentioned,Not Mentioned,"Baseline, 24 Week",Secondary Endpoint
232,NCT01649466,Type 2 Diabetes Mellitus,Change From Baseline In Hba1C At 24 Weeks,Not Mentioned,Not Mentioned,"Baseline, 24 Week",Secondary Endpoint
233,NCT01649466,Type 2 Diabetes Mellitus,Change From Baseline In Treatment Satisfaction Questionnaire For Medication (Tsqm-9) At 24 Week,Not Mentioned,Not Mentioned,"Baseline, 24 Week",Secondary Endpoint
234,NCT03464812,Type2 Diabetes,Program Completion,Not Mentioned,Not Mentioned,Approximately At 4 Months From The Start Of The Study.,Primary Endpoint
235,NCT03464812,Type2 Diabetes,Glycemic Control,Not Mentioned,Not Mentioned,At Baseline And Repeated After Approximately 4 Months,Secondary Endpoint
236,NCT03464812,Type2 Diabetes,Diabetes-Specific Quality Of Life,Not Mentioned,Not Mentioned,At Baseline And Repeated After Approximately 4 Months,Secondary Endpoint
237,NCT03464812,Type2 Diabetes,Diabetes-Related Distress,Not Mentioned,Not Mentioned,At Baseline And Repeated After Approximately 4 Months,Secondary Endpoint
238,NCT03464812,Type2 Diabetes,Diabetes Self-Care,Not Mentioned,Not Mentioned,At Baseline And Repeated After Approximately 4 Months,Secondary Endpoint
239,NCT03464812,Type2 Diabetes,Diabetes-Related Self Efficacy,Not Mentioned,Not Mentioned,At Baseline And Repeated After Approximately 4 Months,Secondary Endpoint
240,NCT03464812,Type2 Diabetes,Patient And Referring Provider Satisfaction,Not Mentioned,Not Mentioned,Approximately At 4 Months From The Start Of The Study.,Secondary Endpoint
241,NCT02501876,Alzheimer´S Disease|Diabetes Mellitus Type 2,The Rate Of Conversion To Alzheimer'S Disease (Ad),Not Mentioned,Not Mentioned,6 Months,Primary Endpoint
242,NCT02501876,Alzheimer´S Disease|Diabetes Mellitus Type 2,The Presence Of Common Alleles For Alzheimer'S Disease (Ad) And Diabetes Mellitus Type 2,Not Mentioned,Not Mentioned,4 Months,Secondary Endpoint
243,NCT03341117,"Diabetes Mellitus, Type 2|Antioxidant Enzyme System","Modification In The Antioxidant Enzymatic System Activity (Total Antioxidant Capacity, Catalase, Glutathione Peroxidase , Superoxide Dismutase) In Patients With Type 2 Diabetes After The Administration Of Acetylsalicylic Acid",Not Mentioned,Not Mentioned,90 Days,Primary Endpoint
244,NCT03341117,"Diabetes Mellitus, Type 2|Antioxidant Enzyme System",Modification In Lipid Profile In Patients With Type 2 Diabetes After The Administration Of Acetylsalicylic Acid,Not Mentioned,Not Mentioned,90 Days,Secondary Endpoint
245,NCT03341117,"Diabetes Mellitus, Type 2|Antioxidant Enzyme System",Hepatic Safety After The Administration Of Acetylsalicylic Acid Through The Determination Of Hepatic Profile,Not Mentioned,Not Mentioned,90 Days,Secondary Endpoint
246,NCT03341117,"Diabetes Mellitus, Type 2|Antioxidant Enzyme System",Renal Safety Of Administration Of Acetylsalicylic Acid Through The Determination Of Serum Creatinine,Not Mentioned,Not Mentioned,90 Days,Secondary Endpoint
247,NCT03341117,"Diabetes Mellitus, Type 2|Antioxidant Enzyme System",Modification In Hba1C In Patients With Type 2 Diabetes After The Administration Of Acetylsalicylic Acid,Not Mentioned,Not Mentioned,90 Days,Secondary Endpoint
248,NCT03341117,"Diabetes Mellitus, Type 2|Antioxidant Enzyme System",Modification In Fasting Glucose In Patients With Type 2 Diabetes After The Administration Of Acetylsalicylic Acid,Not Mentioned,Not Mentioned,90 Days,Secondary Endpoint
249,NCT04214600,Type 2 Diabetes|Depression,Change Of Glycated Hemoglobin A1C (Hb A1C) After The Cognitive Behavioral Therapy Sessions,Not Mentioned,Not Mentioned,Baseline And 3 Months,Primary Endpoint
250,NCT04214600,Type 2 Diabetes|Depression,Change Of Depression Score On Beck'S Depression Index,Not Mentioned,Not Mentioned,Baseline And 3 Months,Secondary Endpoint
251,NCT02860611,Type 1 Diabetes|Type 2 Diabetes,Difference In T Helper Cytokines Between Groups,Not Mentioned,Not Mentioned,6 Months,Primary Endpoint
252,NCT02860611,Type 1 Diabetes|Type 2 Diabetes,Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
253,NCT01037647,Type 2 Diabetes,Vldl-Tg Production And Clearance Rates,Not Mentioned,Not Mentioned,Nan,Primary Endpoint
254,NCT00103935,Type 2 Diabetes Mellitus,"Assess The Safety, Tolerability, And Pharmacokinetics Of Exenatide Long-Acting Release (Lar) Administered Weekly By Subcutaneous (Sc) Injection In Subjects With Type 2 Diabetes (T2Dm)",Not Mentioned,Not Mentioned,"Time Intervals: 0 Min To 12 Hours On Day 1 For A Duration Of 12 Hours, From Day 1; 0 Mininutes To Week 1 For A Duration Of 168 Hours, And From Week 14 To Week 15 For A Duration Of 168 Hours",Primary Endpoint
255,NCT00103935,Type 2 Diabetes Mellitus,Examine The Effect On Various Pharmacodynamic Parameters Of Exenatide Lar Administered Weekly By Subcutaneous Injection In Subjects With Type 2 Diabetes Mellitus,Not Mentioned,Not Mentioned,Various Time Intervals From Day 1 To Week 15,Secondary Endpoint
256,NCT00103935,Type 2 Diabetes Mellitus,"Change In Hba1C (Glycosylated Hemoglobin) From Baseline To Week 15 And To Each Intermediate Visit Where Applicable, And To Study Termination (Week 27).",Not Mentioned,Not Mentioned,"Day -3, Day 1, Weeks 1, 2, 4, 5, 7, 8, 10, 11, 13, 14, 15, 16, 17, 18, 19, 27",Secondary Endpoint
257,NCT00103935,Type 2 Diabetes Mellitus,"Change In Fasting Glucose Concentrations From Baseline To Week 15 And To Each Intermediate Visit Where Applicable, And To Study Termination (Week 27)",Not Mentioned,Not Mentioned,"Day -3, Day 1, Weeks 1, 2, 4, 5, 7, 8, 10, 11, 13, 14, 15, 16, 17, 18, 19, 27",Secondary Endpoint
258,NCT00103935,Type 2 Diabetes Mellitus,"Change In Body Weight From Baseline To Week 15 And To Each Intermediate Visit Where Applicable, And To Study Termination (Week 27)",Not Mentioned,Not Mentioned,"Day -3, Day 1, Weeks 1, 2, 4, 5, 7, 8, 10, 11, 13, 14, 15, 16, 17, 18, 19, 27",Secondary Endpoint
259,NCT00103935,Type 2 Diabetes Mellitus,Change In Seven-Point Glucose Concentrations From Baseline To Week 14 And Week 15,Not Mentioned,Not Mentioned,"Baseline, 3 Days Between Day -7 And Day -3, And 3 Days Between Week 14 And Week 15",Secondary Endpoint
260,NCT00525330,Type 2 Diabetes,The Primary Objective Of This Trial Is To Demonstrate The Hemoglobin A1C (Hba1C)-Lowering Effects Of Krp-104 In Patients With Type 2 Diabetes Inadequately Controlled On Metformin Alone.,Not Mentioned,Not Mentioned,12-Weeks,Primary Endpoint
261,NCT00525330,Type 2 Diabetes,To Assess The Fasting Plasma Glucose (Fpg)-Lowering Effect Of Krp-104 In Patients With Type 2 Diabetes Inadequately Controlled On Metformin Alone;,Not Mentioned,Not Mentioned,12-Weeks,Secondary Endpoint
262,NCT00525330,Type 2 Diabetes,To Compare Effects Of Once Daily (Qd) Dosing Versus Twice Daily (Bid) Dosing Of Krp-104 On Hba1C And Fpg,Not Mentioned,Not Mentioned,12 Weeks,Secondary Endpoint
263,NCT00525330,Type 2 Diabetes,To Assess The Effects Of Krp-104 On Post-Prandial Glucose Dynamics And Insulin Sensitivity (Homeostasis Model Index [Homa-Β]) In The Setting Of A Meal Tolerance Test(Mtt),Not Mentioned,Not Mentioned,12 Weeks,Secondary Endpoint
264,NCT00525330,Type 2 Diabetes,To Assess The Safety And Tolerability Of Krp-104;,Not Mentioned,Not Mentioned,Daily For 12 Weeks To 2 Weeks Post-Treatment,Secondary Endpoint
265,NCT01977560,Type 2 Diabetes,Glycemic Control,Not Mentioned,Not Mentioned,8 Months,Primary Endpoint
266,NCT01977560,Type 2 Diabetes,Glucose Metabolism,Not Mentioned,Not Mentioned,8 Months,Secondary Endpoint
267,NCT01977560,Type 2 Diabetes,Neuronal Function,Not Mentioned,Not Mentioned,8 Months,Secondary Endpoint
268,NCT01977560,Type 2 Diabetes,Acceptability And Feasibility Of Intervention,Not Mentioned,Not Mentioned,8 Months,Secondary Endpoint
269,NCT01278823,Obesity|Type 2 Diabetes,Test The Effect Of Gastric Bypass Surgery On Glycemic Control In Obese Type 2 Dm Patients,Not Mentioned,Not Mentioned,12 Months,Primary Endpoint
270,NCT01278823,Obesity|Type 2 Diabetes,Determine The Effects Of Gastric Bypass Surgery On Pancreatic Beta Cell Function And Incretin Hormone Secretion In Obese Type 2 Dm Patients,Not Mentioned,Not Mentioned,12 Months,Secondary Endpoint
271,NCT01580475,Type 2 Diabetes,"Changes From Baseline In Glycemic Control Measurements (Follow-Up For 21 Months) At Training (9 Months), Detraining (3 Months) And Retraining (9 Months)",Not Mentioned,Not Mentioned,"Changes From Baseline In Hba1C, Fpg And Ppg At Training (9 Months), Detraining (11 Months) And Retraining (21 Months)",Primary Endpoint
272,NCT01580475,Type 2 Diabetes,Evaluation Of Body Composition,Not Mentioned,Not Mentioned,"Changes From Baseline In Body Composition Assessment At Training (9 Months), Detraining (3 Months), Retraining (9 Months)",Secondary Endpoint
273,NCT01580475,Type 2 Diabetes,Peak Oxygen Consumption (Vo2Peak),Not Mentioned,Not Mentioned,"Changes From Baseline In Vo2Peak At Training (9 Months), Detraining (11 Months) And Retraining (21 Months)",Secondary Endpoint
274,NCT01580475,Type 2 Diabetes,Measurement Of Muscular Strength In Patients With Type 2 Diabetes,Not Mentioned,Not Mentioned,"Changes From Baseline In Muscular Strength At Training (9 Months), Detraining (11 Months) And Retraining (21 Months)",Secondary Endpoint
275,NCT00108004,Type 1 Diabetes Mellitus|Type 2 Diabetes Mellitus,To Investigate The Clinical Utility And Safety Of Pramlintide In Subjects With Type 1 And Type 2 Diabetes Mellitus,Not Mentioned,Not Mentioned,6 Months,Primary Endpoint
276,NCT00108004,Type 1 Diabetes Mellitus|Type 2 Diabetes Mellitus,Understand Management Issues In Subjects With Type 1 And Type 2 Diabetes Mellitus,Not Mentioned,Not Mentioned,6 Months,Primary Endpoint
277,NCT00108004,Type 1 Diabetes Mellitus|Type 2 Diabetes Mellitus,Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
278,NCT02222350,Type 2 Diabetes Mellitus,Change In 24-Hour Weighted Mean Blood Glucose,Not Mentioned,Not Mentioned,Day -1 (Baseline) To Day 28,Primary Endpoint
279,NCT02222350,Type 2 Diabetes Mellitus,Change In 24 Hour Weighted Mean Blood Glucose,Not Mentioned,Not Mentioned,Day -1 (Baseline) To Day 14,Secondary Endpoint
280,NCT02222350,Type 2 Diabetes Mellitus,Change In Blood Fasting Plasma Glucose Level,Not Mentioned,Not Mentioned,"Day -1 (Baseline) To Days 7, 14, 21, 28",Secondary Endpoint
281,NCT02222350,Type 2 Diabetes Mellitus,Change In Blood Plasma Glucose Level,Not Mentioned,Not Mentioned,Day -1 (Baseline) To Days 14 And 28,Secondary Endpoint
282,NCT02222350,Type 2 Diabetes Mellitus,Change In Blood Insulin Level,Not Mentioned,Not Mentioned,Day -1 (Baseline) To Days 14 And 28,Secondary Endpoint
283,NCT02222350,Type 2 Diabetes Mellitus,Change In Blood C-Peptide Level,Not Mentioned,Not Mentioned,Day -1 (Baseline) To Days 14 And 28,Secondary Endpoint
284,NCT02222350,Type 2 Diabetes Mellitus,Change In Blood Active Glp-1 Level,Not Mentioned,Not Mentioned,Day -1 (Baseline) To Days 14 And 28,Secondary Endpoint
285,NCT02222350,Type 2 Diabetes Mellitus,Change In Blood Pyy Level,Not Mentioned,Not Mentioned,Day -1 (Baseline) To Days 14 And 28,Secondary Endpoint
286,NCT02222350,Type 2 Diabetes Mellitus,Change In Blood Hba1C Level,Not Mentioned,Not Mentioned,Day -1 (Baseline) To Days 14 And 28,Secondary Endpoint
287,NCT02222350,Type 2 Diabetes Mellitus,Change In Blood Glycoalbumin Level,Not Mentioned,Not Mentioned,Day -1 (Baseline) To Days 14 And 28,Secondary Endpoint
288,NCT02222350,Type 2 Diabetes Mellitus,Number Of Subjects Experiencing Adverse Events As A Measure Of Safety,Not Mentioned,Not Mentioned,Day -1 (Baseline) To Day 28,Secondary Endpoint
289,NCT02222350,Type 2 Diabetes Mellitus,Pharmacokinetic Profile Of Ds-8500A,Not Mentioned,Not Mentioned,Day -1 (Baseline) To Day 28,Secondary Endpoint
290,NCT02222350,Type 2 Diabetes Mellitus,Change In Postprandial Plasma Glucose Level,Not Mentioned,Not Mentioned,Day -1 (Baseline) To Days 14 And 28,Secondary Endpoint
291,NCT02528695,Diabetes Mellitus Type 2,Glucose Uptake In Adipose Tissue Measured By Uptake Of 18F-Fdg On Pet Images,Not Mentioned,Not Mentioned,1 Year,Primary Endpoint
292,NCT02528695,Diabetes Mellitus Type 2,Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
293,NCT00922649,Type 2 Diabetes,Insulin Doses At Week 16,Not Mentioned,Not Mentioned,Week 16,Primary Endpoint
294,NCT00922649,Type 2 Diabetes,Ratio Of Basal-To-Bolus Insulin Dose At Week 16,Not Mentioned,Not Mentioned,16 Weeks,Primary Endpoint
295,NCT00922649,Type 2 Diabetes,Number Of Daily Basal Rates At Week 16,Not Mentioned,Not Mentioned,Week 16,Primary Endpoint
296,NCT00922649,Type 2 Diabetes,A1C (Hemoglobin A1C),Not Mentioned,Not Mentioned,Week 16,Secondary Endpoint
297,NCT00922649,Type 2 Diabetes,7 Point Profile,Not Mentioned,Not Mentioned,Week 16,Secondary Endpoint
298,NCT00922649,Type 2 Diabetes,Cgm Glucose Ranges - Percent Of Measurements,Not Mentioned,Not Mentioned,End Of Study,Secondary Endpoint
299,NCT00922649,Type 2 Diabetes,Body Weight,Not Mentioned,Not Mentioned,Week 16,Secondary Endpoint
300,NCT00922649,Type 2 Diabetes,Hypoglycemia,Not Mentioned,Not Mentioned,Week 16,Secondary Endpoint
301,NCT00922649,Type 2 Diabetes,Change From Baseline To Week 16 In Patient Reported Outcomes (Pros),Not Mentioned,Not Mentioned,Week 16,Secondary Endpoint
302,NCT03324776,Type2 Diabetes,Percentage Change From Baseline Hba1C,Not Mentioned,Not Mentioned,3 Months,Primary Endpoint
303,NCT03324776,Type2 Diabetes,Percentage Of Patients Having Hba1C Under 7%,Not Mentioned,Not Mentioned,3 Months,Secondary Endpoint
304,NCT03324776,Type2 Diabetes,Percent Of Time That Blood Glucose (Bg) Is Under 70 Mg/Dl On Cgms,Not Mentioned,Not Mentioned,3 Months,Secondary Endpoint
305,NCT04163757,Type 2 Diabetes,Type 2 Diabetes,Not Mentioned,Not Mentioned,12 Weeks,Primary Endpoint
306,NCT04163757,Type 2 Diabetes,Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
307,NCT00971659,Type 2 Diabetes,The Unadjusted 6-Hour Postprandial Blood Glucose Excursion (Aucbg0-6H) Following Ingestion Of A Standardized Breakfast,Not Mentioned,Not Mentioned,After 4 Weeks Of Treatment,Primary Endpoint
308,NCT00971659,Type 2 Diabetes,"Mean Daily Blood Glucose (Bg) From 7-Point 24H Bg Profiles, Fasting Bg, Self-Measured 7-Point Bg Profiles, Percentage Of Subjects Achieving Ada Hba1C Treatment Goals, Fasting Lipid Profiles, Homa-Ir Index, Hypoglycemic Episodes",Not Mentioned,Not Mentioned,After 4 Weeks Of Treatment,Secondary Endpoint
309,NCT01607294,Hyperlipidemia|Type 2 Diabetes,Assess The Ldl-C Lowering Efficacy Of Etc-1002 Versus Placebo In Subjects With Type 2 Diabetes,Not Mentioned,Not Mentioned,4 Weeks,Primary Endpoint
310,NCT01607294,Hyperlipidemia|Type 2 Diabetes,Assess The Effect Of Etc-1002 Versus Placebo On Glycemic Parameters Including Fasting Plasma And Postprandial Glucose And Insulin,Not Mentioned,Not Mentioned,4 Weeks,Secondary Endpoint
311,NCT01607294,Hyperlipidemia|Type 2 Diabetes,Assess The Effect Of Etc-1002 Versus Placebo On Measures Of Insulin Sensitivity In Subjects With Type 2 Diabetes,Not Mentioned,Not Mentioned,4 Weeks,Secondary Endpoint
312,NCT01607294,Hyperlipidemia|Type 2 Diabetes,"Assess Safety Using Adverse Event Reports, Physical Exams, Vital Signs, Ecgs And Clinical Laboratory Parameters",Not Mentioned,Not Mentioned,4 Weeks,Secondary Endpoint
313,NCT00299871,Type 2 Diabetes,Hba1C Levels At Baseline And Endpoint (At 13 Weeks).,Not Mentioned,Not Mentioned,Nan,Primary Endpoint
314,NCT00299871,Type 2 Diabetes,"Fructosamine, Fasting Plasma Glucose, Fasting Serum Insulin, Proinsulin, C-Peptide, Glucagon.",Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
315,NCT00303394,Type 2 Diabetes,Hba1C,Not Mentioned,Not Mentioned,Nan,Primary Endpoint
316,NCT00631774,Type 2 Diabetes|Obesity,The Primary Objective Of This Study Is To Evaluate The Effect Of A Diet Program Including Glucerna Sr As A Meal Replacement On Postprandial Glucose Response After Using Glucerna Sr For 24 Weeks In Obese Asian Subjects With Type 2 Diabetes,Not Mentioned,Not Mentioned,24 Weeks,Primary Endpoint
317,NCT00631774,Type 2 Diabetes|Obesity,"Evaluate The Efficacy And Safety Of A Meal Replacement Program With Glucerna Sr Vs. An Edp Based On The Nutrition Therapy Recommendations From The Ada On Anthropometric Measurements, Lipid Profile, Meal-Related Metabolic Changes And Quality Of Life",Not Mentioned,Not Mentioned,24 Weeks,Secondary Endpoint
318,NCT04072523,Type 2 Diabetes,Prevalence Of Left Ventricular Dysfunction,Not Mentioned,Not Mentioned,1 Day,Primary Endpoint
319,NCT04072523,Type 2 Diabetes,Correlation Of Left Ventricular Dysfunction And Heart Failure,Not Mentioned,Not Mentioned,1 Day,Secondary Endpoint
320,NCT02065544,Type 2 Diabetes Mellitus,Hemoglobin A1C,Not Mentioned,Not Mentioned,6-Months,Primary Endpoint
321,NCT02065544,Type 2 Diabetes Mellitus,Lipid Profile,Not Mentioned,Not Mentioned,6 Months,Secondary Endpoint
322,NCT02065544,Type 2 Diabetes Mellitus,Hs-C Reactive Protein,Not Mentioned,Not Mentioned,6 Months,Secondary Endpoint
323,NCT02065544,Type 2 Diabetes Mellitus,Aerobic Fitness,Not Mentioned,Not Mentioned,6 Months,Secondary Endpoint
324,NCT00837408,Diabetes|Hypertension,Type 2 Diabetes,Not Mentioned,Not Mentioned,Cross-Sectional,Primary Endpoint
325,NCT00837408,Diabetes|Hypertension,Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
326,NCT03909269,Diabetic Nephropathy Type 2|Type2 Diabetes,Hba1C Evaluated By The Total Mean Glucose From Continuous Glucose Monitoring,Not Mentioned,Not Mentioned,17 Weeks,Primary Endpoint
327,NCT03909269,Diabetic Nephropathy Type 2|Type2 Diabetes,Erythrocyte Life Span,Not Mentioned,Not Mentioned,4 Weeks,Secondary Endpoint
328,NCT03909269,Diabetic Nephropathy Type 2|Type2 Diabetes,Glycated Albumin,Not Mentioned,Not Mentioned,17 Weeks,Secondary Endpoint
329,NCT03909269,Diabetic Nephropathy Type 2|Type2 Diabetes,Fructosamine,Not Mentioned,Not Mentioned,17 Weeks,Secondary Endpoint
330,NCT03909269,Diabetic Nephropathy Type 2|Type2 Diabetes,Hba1C Evaluated By The Mean Glucose From Continuous Glucose Monitoring For Each Week,Not Mentioned,Not Mentioned,17 Weeks,Secondary Endpoint
331,NCT03909269,Diabetic Nephropathy Type 2|Type2 Diabetes,Blood Volume,Not Mentioned,Not Mentioned,4 Hours,Secondary Endpoint
332,NCT03909269,Diabetic Nephropathy Type 2|Type2 Diabetes,Standard Deviation,Not Mentioned,Not Mentioned,17 Weeks,Secondary Endpoint
333,NCT03909269,Diabetic Nephropathy Type 2|Type2 Diabetes,Coefficient Variation,Not Mentioned,Not Mentioned,17 Weeks,Secondary Endpoint
334,NCT03909269,Diabetic Nephropathy Type 2|Type2 Diabetes,Low Blood Glucose Index,Not Mentioned,Not Mentioned,17 Weeks,Secondary Endpoint
335,NCT03909269,Diabetic Nephropathy Type 2|Type2 Diabetes,High Blood Glucose Index,Not Mentioned,Not Mentioned,17 Weeks,Secondary Endpoint
336,NCT03909269,Diabetic Nephropathy Type 2|Type2 Diabetes,Time In Hypoglycaemic Range Below 3.0 Mmol/L,Not Mentioned,Not Mentioned,17 Weeks,Secondary Endpoint
337,NCT03909269,Diabetic Nephropathy Type 2|Type2 Diabetes,Time In Hypoglycaemic Range Below 3.9 Mmol/L To 3.0 Mmol/L,Not Mentioned,Not Mentioned,17 Weeks,Secondary Endpoint
338,NCT03909269,Diabetic Nephropathy Type 2|Type2 Diabetes,Time In Target Range From 3.9 Mmol/L To 10.0 Mmol/L,Not Mentioned,Not Mentioned,17 Weeks,Secondary Endpoint
339,NCT03909269,Diabetic Nephropathy Type 2|Type2 Diabetes,Time In Hyperglycaemic Range Above 10.0 Mmol/L,Not Mentioned,Not Mentioned,17 Weeks,Secondary Endpoint
340,NCT03909269,Diabetic Nephropathy Type 2|Type2 Diabetes,Time In Hyperglycaemic Range Above 13.9 Mmol/L,Not Mentioned,Not Mentioned,17 Weeks,Secondary Endpoint
341,NCT03909269,Diabetic Nephropathy Type 2|Type2 Diabetes,Hypoglycaemic Events,Not Mentioned,Not Mentioned,17 Weeks,Secondary Endpoint
342,NCT00477581,Type 2 Diabetes Mellitus,Effect Of Exenatide On Postprandial Glucose,Not Mentioned,Not Mentioned,28 Days,Primary Endpoint
343,NCT00477581,Type 2 Diabetes Mellitus,"Assessment Of Effect Of Exenatide To The Effect Of Sitagliptin The Acetaminophen Absorption Test, And 6-Point Self-Monitored Blood Glucose (Smbg) Profiles",Not Mentioned,Not Mentioned,28 Days,Secondary Endpoint
344,NCT00799643,Type 2 Diabetes Mellitus,"The Primary Outcome For The Tinsal-T2D Study Is Change In Hba1C Level From Baseline To Week 48 From Baseline, Compared Between Treatment Groups.",Not Mentioned,Not Mentioned,48 Weeks From Baseline,Primary Endpoint
345,NCT00799643,Type 2 Diabetes Mellitus,Change From Baseline In Fasting Glucose Over Time.,Not Mentioned,Not Mentioned,48 Weeks From Baseline,Secondary Endpoint
346,NCT00799643,Type 2 Diabetes Mellitus,"Response Rates For Reduction In Fasting Glucose Of ≥20 Mg/Dl, A Reduction In Hba1C Of ≥0.5%, And A Reduction In Hba1C Of ≥0.8%",Not Mentioned,Not Mentioned,24 And 48 Weeks,Secondary Endpoint
347,NCT00799643,Type 2 Diabetes Mellitus,"Change In Lipids (Low-Density Lipoprotein Cholesterol [Ldl-C], Non-High-Density Lipoprotein Cholesterol [Non-Hdl-C], Triglycerides [Tg], Total Cholesterol [Tc], High-Density Lipoprotein Cholesterol [Hdl C], Tc/Hdl-C Ratio, And Ldl-C/Hdl-C Ratio)",Not Mentioned,Not Mentioned,48 Weeks,Secondary Endpoint
348,NCT00799643,Type 2 Diabetes Mellitus,"Changes In Wbc And Differential, High-Sensitivity C Reactive Protein (Hscrp), Other Inflammatory Markers",Not Mentioned,Not Mentioned,24 And 48 Weeks,Secondary Endpoint
349,NCT00799643,Type 2 Diabetes Mellitus,Response Rates For Exceeding Hyperglycemic Targets Between Active And Placebo Treated Groups; Need For Rescue Therapy; Need For Discontinuation Of Study Medication,Not Mentioned,Not Mentioned,24 And 48 Weeks,Secondary Endpoint
350,NCT00799643,Type 2 Diabetes Mellitus,"Response Rates In Patients Initially Treated With Lifestyle Modification, Insulin Secretagogue, Metformin Or Combination Therapy",Not Mentioned,Not Mentioned,24 And 48 Weeks,Secondary Endpoint
351,NCT01640873,Type 2 Diabetes,Number Of Participants With One Or More Adverse Events,Not Mentioned,Not Mentioned,Up To 14 Days After The Last Dose Of Study Drug (Up To 31 Days),Primary Endpoint
352,NCT01640873,Type 2 Diabetes,Number Of Participants Discontinuing Study Drug Due To An Adverse Event,Not Mentioned,Not Mentioned,Up To 17 Days,Primary Endpoint
353,NCT01640873,Type 2 Diabetes,Fasting Plasma Glucose (Fpg),Not Mentioned,Not Mentioned,Day 16 (Predose),Primary Endpoint
354,NCT01640873,Type 2 Diabetes,True Geometric Mean Plasma Concentrations Of Mk-8655 After Single And Multiple Drug Doses At 24 Hours Post Dose (C24),Not Mentioned,Not Mentioned,"24 Hours Post Dose On Days 1, 7, And 14",Secondary Endpoint
355,NCT01640873,Type 2 Diabetes,24-Hour Weighted Mean Glucose (Wmg),Not Mentioned,Not Mentioned,"Day 15: Predose, 2, 3, 4, 5, 6, 7, 8, 9, 11, 12, 13, 14, 15, 16, 18, 21, 23 Hours Post-Dose.",Secondary Endpoint
356,NCT01640873,Type 2 Diabetes,Change From Baseline At 2 Hours Oral Glucose Tolerance Test,Not Mentioned,Not Mentioned,"Baseline And 2 Hours After Dosing On Days 1, 3, And 16",Secondary Endpoint
357,NCT01732705,Type 2 Diabetes,Insulin Sensitivity,Not Mentioned,Not Mentioned,2 Days After Last Training Session (Day 17),Primary Endpoint
358,NCT01732705,Type 2 Diabetes,Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
359,NCT01159249,Type 2 Diabetes,"Measure Aes, Vital Signs, Laboratory Evaluations",Not Mentioned,Not Mentioned,52 Weeks,Primary Endpoint
360,NCT01159249,Type 2 Diabetes,Hba1C,Not Mentioned,Not Mentioned,52 Weeks,Secondary Endpoint
361,NCT01159249,Type 2 Diabetes,Fasting Plasma Glucose,Not Mentioned,Not Mentioned,52 Weeks,Secondary Endpoint
362,NCT01159249,Type 2 Diabetes,Fasting Insulin,Not Mentioned,Not Mentioned,52 Weeks,Secondary Endpoint
363,NCT01159249,Type 2 Diabetes,Fasting C-Peptide,Not Mentioned,Not Mentioned,52 Weeks,Secondary Endpoint
364,NCT01159249,Type 2 Diabetes,Homa-B,Not Mentioned,Not Mentioned,52 Weeks,Secondary Endpoint
365,NCT00106808,Type 2 Diabetes Mellitus,Change In Hba1C From Baseline To Week 24,Not Mentioned,Not Mentioned,Nan,Primary Endpoint
366,NCT04176276,Diabetic Kidney Disease|Type2 Diabetes,Serum Expression Of Mir-192,Not Mentioned,Not Mentioned,Each Patients Will Be Assessed At Baseline.,Primary Endpoint
367,NCT04176276,Diabetic Kidney Disease|Type2 Diabetes,Serum Expression Of Mir-25,Not Mentioned,Not Mentioned,Each Patients Will Be Assessed At Baseline.,Primary Endpoint
368,NCT04176276,Diabetic Kidney Disease|Type2 Diabetes,Urine Expression Of Mir-192,Not Mentioned,Not Mentioned,Each Patients Will Be Assessed At Baseline.,Primary Endpoint
369,NCT04176276,Diabetic Kidney Disease|Type2 Diabetes,Urine Expression Of Mir-25,Not Mentioned,Not Mentioned,Each Patients Will Be Assessed At Baseline.,Primary Endpoint
370,NCT04176276,Diabetic Kidney Disease|Type2 Diabetes,Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
371,NCT01663220,Type 2 Diabetes,Nan,Not Mentioned,Not Mentioned,Nan,Primary Endpoint
372,NCT01663220,Type 2 Diabetes,Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
373,NCT03902288,Patients With Type 2 Diabetes (Fsg: More Than 7.1 And Not Higher Than 15.8 Mmol/L),Fasting Serum Glucose Measurement,Not Mentioned,Not Mentioned,1 - 3 Hours,Primary Endpoint
374,NCT03902288,Patients With Type 2 Diabetes (Fsg: More Than 7.1 And Not Higher Than 15.8 Mmol/L),Insulin Hormone Measurement,Not Mentioned,Not Mentioned,1 - 3 Hours,Primary Endpoint
375,NCT03902288,Patients With Type 2 Diabetes (Fsg: More Than 7.1 And Not Higher Than 15.8 Mmol/L),Erythropoietin Hormone Measurement,Not Mentioned,Not Mentioned,1 - 3 Hours,Primary Endpoint
376,NCT03902288,Patients With Type 2 Diabetes (Fsg: More Than 7.1 And Not Higher Than 15.8 Mmol/L),Thyroxine Hormone Measurement,Not Mentioned,Not Mentioned,1 - 3 Hours,Primary Endpoint
377,NCT03902288,Patients With Type 2 Diabetes (Fsg: More Than 7.1 And Not Higher Than 15.8 Mmol/L),Cortisol Hormone Measurement,Not Mentioned,Not Mentioned,1 -3 Hours,Primary Endpoint
378,NCT03902288,Patients With Type 2 Diabetes (Fsg: More Than 7.1 And Not Higher Than 15.8 Mmol/L),Melatonin Hormone Measurement,Not Mentioned,Not Mentioned,1 - 3 Hours,Secondary Endpoint
379,NCT03902288,Patients With Type 2 Diabetes (Fsg: More Than 7.1 And Not Higher Than 15.8 Mmol/L),Testosterone Hormone Measurement,Not Mentioned,Not Mentioned,1 - 3 Hours,Secondary Endpoint
380,NCT03902288,Patients With Type 2 Diabetes (Fsg: More Than 7.1 And Not Higher Than 15.8 Mmol/L),Aldosterone Hormone Measurement,Not Mentioned,Not Mentioned,1 - 3 Hours,Secondary Endpoint
381,NCT03902288,Patients With Type 2 Diabetes (Fsg: More Than 7.1 And Not Higher Than 15.8 Mmol/L),Serum Total Antioxidant Activity Measurement,Not Mentioned,Not Mentioned,1 - 3 Hours,Secondary Endpoint
382,NCT03538743,Type 2 Diabetes Mellitus,Number Of Participants With All-Causality And Treatment-Related Treatment-Emergent Adverse Events (Teaes),Not Mentioned,Not Mentioned,From Baseline To Up To 35 Days After Last Dose For A Total Of Approximately 63 Days,Primary Endpoint
383,NCT03538743,Type 2 Diabetes Mellitus,Number Of Participants With Laboratory Abnormalities Without Regard To Baseline Abnormality,Not Mentioned,Not Mentioned,From Baseline To Up To 14 Days After Last Dose For A Total Of Approximately 42 Days,Primary Endpoint
384,NCT03538743,Type 2 Diabetes Mellitus,Number Of Participants With Abnormal Vital Signs,Not Mentioned,Not Mentioned,From Baseline To Up To 14 Days After Last Dose For A Total Of Approximately 42 Days,Primary Endpoint
385,NCT03538743,Type 2 Diabetes Mellitus,Number Of Participants With Abnormal Electrocardiogram (Ecg) Interval,Not Mentioned,Not Mentioned,From Baseline To Up To 14 Days After Last Dose For A Total Of Approximately 42 Days,Primary Endpoint
386,NCT03538743,Type 2 Diabetes Mellitus,"Auc24 And Auctau Of Pf-06882961 On Day 1, Day 14 Or 21 And Day 28",Not Mentioned,Not Mentioned,"0, 1, 2, 4, 6, 8, 10, 12, 14 And 24 Hrs Post Dose On Day 1, 14 Or 21, And 28",Secondary Endpoint
387,NCT03538743,Type 2 Diabetes Mellitus,"Maximum Plasma Concentration (Cmax) Of Pf-06882961 On Day 1, Day 14 Or 21 And Day 28",Not Mentioned,Not Mentioned,"0, 1, 2, 4, 6, 8, 10, 12, 14 And 24 Hours Post Dose On Day 1, 14 Or 21, And 28",Secondary Endpoint
388,NCT03538743,Type 2 Diabetes Mellitus,"Time For Cmax (Tmax) Of Pf-06882961 On Day 1, Day 14 Or 21 And Day 28",Not Mentioned,Not Mentioned,"0, 1, 2, 4, 6, 8, 10, 12, 14 And 24 Hrs Post Dose On Day 1, 14 Or 21, And 28",Secondary Endpoint
389,NCT03538743,Type 2 Diabetes Mellitus,Terminal Half-Life (T½) Of Pf-06882961 On Day 28,Not Mentioned,Not Mentioned,"0, 1, 2, 4, 6, 8, 10, 12, 14 And 24 Hrs Post Dose On Day 28",Secondary Endpoint
390,NCT03538743,Type 2 Diabetes Mellitus,Amount Of Unchanged Drug Recovered In Urine Over 24 Hours (Ae24) Of Pf-06882961 On Day 28,Not Mentioned,Not Mentioned,0 To 24 Hours Post-Dose On Day 28,Secondary Endpoint
391,NCT03538743,Type 2 Diabetes Mellitus,Ae24 (%) Of Pf-06882961 On Day 28,Not Mentioned,Not Mentioned,0 To 24 Hours Post-Dose On Day 28,Secondary Endpoint
392,NCT03538743,Type 2 Diabetes Mellitus,Renal Clearance (Clr) Of Pf-06882961 On Day 28,Not Mentioned,Not Mentioned,0 To 24 Hours Post-Dose On Day 28,Secondary Endpoint
393,NCT01472185,Type 2 Diabetes Mellitus,Change From Baseline In Glycosylated Hemoglobin (Hba1C) At Week 24,Not Mentioned,Not Mentioned,Baseline; Week 24,Primary Endpoint
394,NCT01472185,Type 2 Diabetes Mellitus,Change From Baseline In Fasting Serum Glucose At Week 24,Not Mentioned,Not Mentioned,Baseline; Week 24,Secondary Endpoint
395,NCT01472185,Type 2 Diabetes Mellitus,Percentage Of Participants With Hba1C < 7% At Week 24,Not Mentioned,Not Mentioned,Week 24,Secondary Endpoint
396,NCT01472185,Type 2 Diabetes Mellitus,Change From Baseline In 2-Hour Postprandial Serum Glucose At Week 24,Not Mentioned,Not Mentioned,Baseline; Week 24,Secondary Endpoint
397,NCT01472185,Type 2 Diabetes Mellitus,Change From Baseline In Incremental Change Of 2-Hour Postprandial Serum Glucose At Week 24,Not Mentioned,Not Mentioned,Baseline; Week 24,Secondary Endpoint
398,NCT01494987,Type 2 Diabetes Mellitus,Change From Baseline In Glycosylated Hemoglobin (Hba1C) At Week 24,Not Mentioned,Not Mentioned,Baseline; Week 24,Primary Endpoint
399,NCT01494987,Type 2 Diabetes Mellitus,Change From Baseline In Incremental Change Of 2-Hour Postprandial Serum Glucose At Week 24,Not Mentioned,Not Mentioned,Baseline; Week 24,Secondary Endpoint
400,NCT01494987,Type 2 Diabetes Mellitus,Change From Baseline In Fasting Serum Glucose At Week 24,Not Mentioned,Not Mentioned,Baseline; Week 24,Secondary Endpoint
401,NCT01494987,Type 2 Diabetes Mellitus,Change From Baseline In 2-Hour Postprandial Serum Glucose At Week 24,Not Mentioned,Not Mentioned,Baseline; Week 24,Secondary Endpoint
402,NCT02343471,Healthy|Type 2 Diabetes,Effect On Triglyceride Response Of Whey Protein As Pre-Meal After A High-Fat Meal In Healthy Subjects And Subjects With Type 2 Diabetes Measured As Incremental Area Under The Curve (Iauc -15 - 360 Min).,Not Mentioned,Not Mentioned,"Prior To The Pre Meal (-15 Min), Prior To The Main Meal (0 Min) And 60, 90, 120, 180, 240 And 360 Min Post Main Meal",Primary Endpoint
403,NCT02343471,Healthy|Type 2 Diabetes,Effect On Apolipoprotein B48 Of Whey Protein As Pre-Meal After A High-Fat Meal In Healthy Subjects And Subjects With Type 2 Diabetes Measured As Incremental Area Under The Curve (Iauc -15 - 360 Min).,Not Mentioned,Not Mentioned,"Prior To The Pre Meal (-15 Min), Prior To The Main Meal (0 Min) And 120, 240 And 360 Min Post Main Meal",Primary Endpoint
404,NCT02343471,Healthy|Type 2 Diabetes,Glucose Responses Measured As Incremental Area Under The Curve (Auc -15 - 360 Min),Not Mentioned,Not Mentioned,"Prior To The Pre Meal -15 Min, -10 Min, Prior To The Main Meal (0 Min) And 15, 30, 60, 90, 120, 240 And 360 Min Post Main Meal",Secondary Endpoint
405,NCT02343471,Healthy|Type 2 Diabetes,Insulin Responses Measured As Incremental Area Under The Curve (Auc -15 - 360 Min),Not Mentioned,Not Mentioned,"Prior To The Pre Meal -15 Min, -10 Min, Prior To The Main Meal (0 Min) And 15, 30, 60, 90, 120, 240 And 360 Min Post Main Meal",Secondary Endpoint
406,NCT02343471,Healthy|Type 2 Diabetes,Glucagon Responses Measured As Incremental Area Under The Curve (Auc -15 - 360 Min),Not Mentioned,Not Mentioned,"Prior To The Pre Meal -15 Min, -10 Min, Prior To The Main Meal (0 Min) And 15, 30, 60, 90, 120, 240 And 360 Min Post Main Meal",Secondary Endpoint
407,NCT02343471,Healthy|Type 2 Diabetes,Glucagon-Like Peptide 1 (Glp-1) Responses Measured As Incremental Area Under The Curve (Auc -15 - 360 Min),Not Mentioned,Not Mentioned,"Prior To The Pre Meal -15 Min, -10 Min, Prior To The Main Meal (0 Min) And 15, 30, 60, 90, 120, 240 And 360 Min Post Main Meal",Secondary Endpoint
408,NCT02343471,Healthy|Type 2 Diabetes,Gastric Inhibitory Peptide (Gip) Responses Measured As Incremental Area Under The Curve (Auc -15 - 360 Min).,Not Mentioned,Not Mentioned,"Prior To The Pre Meal -15 Min, -10 Min, Prior To The Main Meal (0 Min) And 15, 30, 60, 90, 120, 240 And 360 Min Post Main Meal",Secondary Endpoint
409,NCT01755468,Type 2 Diabetes,"Baseline-Adjusted Beta-Cell Function At 2 Years, Measured By Insulin Secretion-Sensitivity Index-2 (Issi-2).",Not Mentioned,Not Mentioned,2 Years,Primary Endpoint
410,NCT01755468,Type 2 Diabetes,Baseline-Adjusted Glycemic Control At 2-Years.,Not Mentioned,Not Mentioned,2 Years,Secondary Endpoint
411,NCT04363710,Type 2 Diabetes Mellitus In Obese,Hba1C In Percentage,Not Mentioned,Not Mentioned,Up To 24 Weeks,Primary Endpoint
412,NCT04363710,Type 2 Diabetes Mellitus In Obese,Fasting Blood Glucose In Millimoles Per Liter And Fasting Insulin Level In Picomole Per Liter Will Be Combined To Report Homa Ir,Not Mentioned,Not Mentioned,Up To 24 Weeks,Primary Endpoint
413,NCT04363710,Type 2 Diabetes Mellitus In Obese,Weight In Kilogram And Height In Meters Will Be Combined To Report Bmi In Kg/M^2,Not Mentioned,Not Mentioned,Up To 24 Weeks,Primary Endpoint
414,NCT04363710,Type 2 Diabetes Mellitus In Obese,Nan,Not Mentioned,Not Mentioned,Nan,Secondary Endpoint
415,NCT00562029,Type 2 Diabetes Mellitus,Measure: Resolution Of Type 2 Diabetes Mellitus,Not Mentioned,Not Mentioned,One Year,Primary Endpoint
416,NCT00562029,Type 2 Diabetes Mellitus,Measure: Safety And Efficacy Of Duodenal-Jejunal Bypass,Not Mentioned,Not Mentioned,One Year,Secondary Endpoint
